Oramed Pharmaceuticals (ORMP) Earning Somewhat Favorable Media Coverage, Analysis Finds

Media coverage about Oramed Pharmaceuticals (NASDAQ:ORMP) has trended somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.5706567865892 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several brokerages have recently weighed in on ORMP. ValuEngine upgraded Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 31st. HC Wainwright set a $25.00 target price on Oramed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, June 6th. Finally, B. Riley cut Oramed Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, July 16th.

Oramed Pharmaceuticals traded down $0.11, reaching $4.78, during trading hours on Friday, according to Marketbeat Ratings. The company’s stock had a trading volume of 75,601 shares, compared to its average volume of 56,972. Oramed Pharmaceuticals has a fifty-two week low of $4.70 and a fifty-two week high of $11.34. The stock has a market capitalization of $84.90 million, a PE ratio of -6.05 and a beta of 0.39.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Thursday, July 12th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Oramed Pharmaceuticals had a negative net margin of 204.00% and a negative return on equity of 63.20%. The business had revenue of $0.62 million during the quarter, compared to analyst estimates of $0.61 million. equities analysts predict that Oramed Pharmaceuticals will post -0.92 earnings per share for the current year.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.

See Also: Marijuana Stocks Future Looks Bright

Insider Buying and Selling by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply